High H. pylori cure rate for nonbismuth quadruple Tx

July 29, 2013
High <i>H. pylori</i> cure rate for nonbismuth quadruple tx
Optimized nonbismuth quadruple regimens, either hybrid or concomitant, have a cure rate of more than 90 percent for Helicobacter pylori infections, according to a study published in the July issue of Gastroenterology.

(HealthDay)—Optimized nonbismuth quadruple regimens, either hybrid or concomitant, have a cure rate of more than 90 percent for Helicobacter pylori (H. pylori) infections, according to a study published in the July issue of Gastroenterology.

Javier Molina-Infante, M.D., from the Hospital San Pedro de Alcantara in Caceres, Spain, and colleagues compared the efficacy of two optimized nonbismuth quadruple regimens among 343 consecutive individuals with H. pylori infection. Participants were randomized to receive hybrid therapy ( and , twice daily for 14 days, plus clarithromycin and nitroimidazole twice daily for final seven days) or concomitant therapy (same drugs taken concurrently, twice daily for 14 days).

The researchers found that rates of eradication for hybrid and concomitant therapies were 92 and 96.1 percent, respectively (P = 0.07), in per-protocol analysis. The rates were 90 and 91.7 percent, respectively (P = 0.35) in intention-to-treat analysis. Full compliance was high at 95.5 percent. H. pylori strains that were resistant to clarithromycin, , and both drugs were seen in 23.5, 33, and 8.8 percent of patients, respectively. Nearly half (51.5 percent) of patients reported mild side effects. The only significant predictor of eradication was compliance greater than 80 percent (odds ratio, 12.5). Compliance was significantly higher for hybrid therapy versus concomitant therapy (98.8 versus 95.2 percent; P = 0.05).

"Optimized nonbismuth quadruple hybrid and concomitant therapies cured more than 90 percent of patients with H. pylori infections in areas of high and metronidazole resistance," the authors write.

Explore further: Ironing out the link between H. pylori infection and gastric cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.